Treatment patterns and outcomes in patients with metastatic synovial sarcoma in France, Germany, Italy, Spain and the UK
Aim: Describing the treatment patterns, outcomes by line of treatment (LOT), and healthcare resource utilization (HCRU) in patients with metastatic synovial sarcoma (mSS). Patients & methods: In this descriptive, non-interventional, retrospective cohort study, physicians from five European countries reported on patients with recent pharmacological treatment for mSS. Results: Among 296 patients with mSS, 86.1, 38.9 and 8.4% received 1 LOT (1L), 2 LOTs (2L) and 3+ LOTs (L3+), respectively. Common regimens were doxorubicin/ifosfamide-based (37.4%) for 1L and trabectedin-based for 2L (29.7%). For 1L, median time to next treatment was 13.1 and 6.0 months for living and deceased patients, respectively. Median OS was 22.0, 6.0 and 4.9 months in all patients, 2L and 3L, respectively. HCRU data showed median one inpatient hospital admission, 3 days in hospital and four outpatient visits yearly. Conclusion: This large-scale study documents high unmet needs in patients previously treated for mSS and for more effective therapies.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:19 |
|---|---|
| Enthalten in: |
Future oncology (London, England) - 19(2023), 18 vom: 04. Juni, Seite 1261-1275 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Patel, Nashita [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Delivery of healthcare |
|---|
| Anmerkungen: |
Date Completed 21.07.2023 Date Revised 21.07.2023 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.2217/fon-2022-1005 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM356430715 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM356430715 | ||
| 003 | DE-627 | ||
| 005 | 20231226070439.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.2217/fon-2022-1005 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1188.xml |
| 035 | |a (DE-627)NLM356430715 | ||
| 035 | |a (NLM)37139794 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Patel, Nashita |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Treatment patterns and outcomes in patients with metastatic synovial sarcoma in France, Germany, Italy, Spain and the UK |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 21.07.2023 | ||
| 500 | |a Date Revised 21.07.2023 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Aim: Describing the treatment patterns, outcomes by line of treatment (LOT), and healthcare resource utilization (HCRU) in patients with metastatic synovial sarcoma (mSS). Patients & methods: In this descriptive, non-interventional, retrospective cohort study, physicians from five European countries reported on patients with recent pharmacological treatment for mSS. Results: Among 296 patients with mSS, 86.1, 38.9 and 8.4% received 1 LOT (1L), 2 LOTs (2L) and 3+ LOTs (L3+), respectively. Common regimens were doxorubicin/ifosfamide-based (37.4%) for 1L and trabectedin-based for 2L (29.7%). For 1L, median time to next treatment was 13.1 and 6.0 months for living and deceased patients, respectively. Median OS was 22.0, 6.0 and 4.9 months in all patients, 2L and 3L, respectively. HCRU data showed median one inpatient hospital admission, 3 days in hospital and four outpatient visits yearly. Conclusion: This large-scale study documents high unmet needs in patients previously treated for mSS and for more effective therapies | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Europe | |
| 650 | 4 | |a delivery of healthcare | |
| 650 | 4 | |a health resources | |
| 650 | 4 | |a practice patterns, physicians | |
| 650 | 4 | |a sarcoma, synovial | |
| 650 | 4 | |a treatment outcome | |
| 650 | 7 | |a Trabectedin |2 NLM | |
| 650 | 7 | |a ID0YZQ2TCP |2 NLM | |
| 700 | 1 | |a Pokras, Shibani |e verfasserin |4 aut | |
| 700 | 1 | |a Ferma, Jane |e verfasserin |4 aut | |
| 700 | 1 | |a Casey, Vicky |e verfasserin |4 aut | |
| 700 | 1 | |a Manuguid, Fil |e verfasserin |4 aut | |
| 700 | 1 | |a Culver, Ken |e verfasserin |4 aut | |
| 700 | 1 | |a Bauer, Sebastian |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Future oncology (London, England) |d 2005 |g 19(2023), 18 vom: 04. Juni, Seite 1261-1275 |w (DE-627)NLM161450725 |x 1744-8301 |7 nnns |
| 773 | 1 | 8 | |g volume:19 |g year:2023 |g number:18 |g day:04 |g month:06 |g pages:1261-1275 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.2217/fon-2022-1005 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 19 |j 2023 |e 18 |b 04 |c 06 |h 1261-1275 | ||